Provided by Tiger Fintech (Singapore) Pte. Ltd.

Glaukos

92.99
+0.30000.32%
Post-market: 92.990.00000.00%19:10 EDT
Volume:653.29K
Turnover:61.03M
Market Cap:5.31B
PE:-40.99
High:95.00
Open:94.34
Low:92.92
Close:92.69
Loading ...

56% Of This Glaukos Insider's Holdings Were Sold

Simply Wall St.
·
08 Feb

Mesa Labs (MLAB) Q3 Earnings and Revenues Beat Estimates

Zacks
·
04 Feb

Glaukos Price Target Raised to $180.00/Share From $140.00 by Piper Sandler

Dow Jones
·
27 Jan

Glaukos price target raised to $180 from $140 at Piper Sandler

TIPRANKS
·
27 Jan

Piper Sandler Sticks to Their Buy Rating for Glaukos (GKOS)

TIPRANKS
·
27 Jan

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

Business Wire
·
23 Jan

NeuroPace (NPCE) Soars 9.1%: Is Further Upside Left in the Stock?

Zacks
·
22 Jan

Wells Fargo Sticks to Their Buy Rating for Glaukos (GKOS)

TIPRANKS
·
16 Jan

Glaukos Highlights Advances in Glaucoma Treatments

TIPRANKS
·
15 Jan

Glaukos says iDose TR showed sustained substantial IOP reductions in Phase 3

TIPRANKS
·
15 Jan

Glaukos Reaches 52-Week High: What's Driving the Stock's Rally?

Zacks
·
08 Jan

BTIG Sticks to Their Buy Rating for Glaukos (GKOS)

TIPRANKS
·
07 Jan

Glaukos price target raised to $157 from $149 at BTIG

TIPRANKS
·
03 Jan

Glaukos Corp : Stifel Raises Target Price to $175 From $153

THOMSON REUTERS
·
31 Dec 2024

Stifel Adjusts Price Target on Glaukos to $175 From $153, Keeps Buy Rating

MT Newswires Live
·
31 Dec 2024

Glaukos price target raised to $175 from $153 at Stifel

TIPRANKS
·
31 Dec 2024

Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA

Zacks
·
25 Dec 2024

Glaukos submits NDA to U.S. FDA for Epioxa to treat keratoconus

TIPRANKS
·
23 Dec 2024

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

THOMSON REUTERS
·
23 Dec 2024

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

Business Wire
·
23 Dec 2024